Ipamorelin 5 mg

Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release more growth hormone naturally. Unlike older secretagogues, it specifically targets GH release without affecting cortisol, prolactin, ACTH, or appetite hormones.

Increased GH stimulates the liver to produce IGF-1, which mediates muscle growth, fat loss, tissue repair, and anti-aging benefits. Ipamorelin is commonly referenced for recovery support, body composition, and sleep quality.

Ipamorelin exhibits minimal cortisol and prolactin elevation in published studies, while sermorelin carries moderate risk of endocrine shifts at higher doses. Both require baseline screening and provider oversight.

Individual safety depends on metabolic health, baseline hormones, and drug interactions. Ipamorelin's selectivity for GH release without affecting stress hormones is a distinguishing characteristic.

Common adverse effects are usually mild and may include injection site irritation, mild fluid retention, or transient joint aches. Long-term safety data remains sparse, and individual tolerability varies.

Potential concerns include appetite stimulation in some users (which may counteract weight-loss goals) and ghrelin-mediated effects on cortisol and sleep in sensitive individuals. Ipamorelin is not for use in people with active cancers, untreated diabetic retinopathy, or severe systemic illness.

Ipamorelin is commonly referenced in non-medical contexts for body composition support, including fat loss. The rationale is that increased GH and IGF-1 levels may support lipolysis and lean mass preservation. CJC-1295 plus ipamorelin is a commonly referenced research peptide stack for fat loss, though there are no published human randomized controlled trials on this combination for fat loss specifically.

Animal studies have shown that GH secretagogues can increase body fat through GH-independent mechanisms that may include increased feeding, which is a consideration for fat-loss goals. Individual results depend on nutrition, exercise, and metabolic factors.

Ipamorelin 5 mg contains the research peptide ipamorelin in lyophilized powder form. It is supplied for research and educational purposes. In research contexts, ipamorelin has been studied as a growth hormone secretagogue for its selective GH-releasing properties.

It is not an FDA-approved human pharmaceutical product and is not intended for human use outside approved research contexts.

Frequency of use depends on the specific research or non-medical context. In self-reported protocols, ipamorelin is commonly referenced at 200–300 mcg per injection, administered 2–3 times daily. Optimal timing includes upon waking (fasted), post-workout, and 30–60 minutes before bed. These frequencies are for educational reference only.

Post-cycle therapy is not applicable to ipamorelin, as it is not a compound that suppresses the hypothalamic-pituitary-gonadal axis. It is a growth hormone secretagogue that stimulates endogenous GH release.

When ipamorelin is used as part of a broader research protocol that includes anabolic compounds, standard PCT protocols such as those involving Clomixyl or Nolvaxyl would be relevant to those compounds, not to ipamorelin itself.

Ipamorelin binds to ghrelin receptors in the pituitary gland to stimulate growth hormone secretion through natural pathways without affecting other hormones. It creates GH pulses that mimic the body's natural secretion patterns, supporting physiological hormone balance.

Increased GH stimulates the liver to produce IGF-1, which mediates muscle growth, fat loss, tissue repair, and anti-aging benefits.

Ipamorelin has a half-life of about 2 hours, with GH release occurring in a pulsatile manner after injection. However, observable changes in body composition or recovery typically develop gradually over weeks to months.

Clinical studies on GH secretagogues report IGF-1 elevation of 10–30% across responder populations, with individual variation significant. Realistic timelines span 4–8 weeks minimum for measurable changes.

There is no single growth hormone secretagogue that is universally best. Ipamorelin is considered one of the most selective and well-tolerated GH secretagogues, with minimal cortisol or prolactin effects. Tesamorelin 5 mg is a GHRH analog with FDA approval for a specific indication, while Kalpatropin HGH provides exogenous somatropin.

The appropriate choice depends on the specific research or clinical context.

Ipamorelin 5 mg contains the ghrelin receptor agonist ipamorelin, which stimulates GH release through the ghrelin pathway with minimal cortisol or prolactin effects. Tesamorelin 5 mg is a GHRH analog that directly stimulates pituitary GH release and has FDA approval for a specific indication.

These are different compounds with different mechanisms and clinical evidence bases.

The milligram strength of the vial (5 mg) refers to the total amount of ipamorelin in the vial, not the amount administered per dose. The dose administered depends on how the powder is reconstituted and the specific protocol being followed.

It is important to distinguish vial strength from administered dose. A 5 mg vial can be reconstituted with an appropriate volume of diluent to achieve the desired concentration for research or educational purposes. For example, adding 2.5 mL of bacteriostatic water to a 5 mg vial produces a concentration of 2000 mcg/mL.

Ipamorelin is expected to be moved from the FDA's Category 2 restricted compounding list back to Category 1 in 2026, which would allow licensed compounding pharmacies to prepare it with a valid prescription. However, Category 1 status does not constitute FDA approval, and the FDA's Pharmacy Compounding Advisory Committee is scheduled to formally review it in July 2026.

Ipamorelin is also prohibited for use by athletes under WADA and USADA guidelines.